MAPT (Tau) expression is a biomarker for an increased rate of survival for low‑grade glioma.The association of MAPT (Tau) with various tauopathies and other neurological disorders has long been established.  However, the role of microtubule‑associated protein Tau (MAPT) expression in brain cancer is largely unknown.  To determine whether MAPT expression is related to low‑grade glioma (LGG) survival rates, RNASeq data representing samples from the Cancer Genome Atlas (TCGA) were assessed.  Results revealed that high expression of the MAPT gene is very strongly associated with increased overall and disease‑free survival in LGG but not in breast cancer or melanoma. 
MAPT
To determine whether MAPT expression is related to low‑grade glioma (LGG) survival rates, RNASeq data representing samples from the Cancer Genome Atlas (TCGA) were assessed. 
RNASeq
To determine whether MAPT expression is related to low‑grade glioma (LGG) survival rates, RNASeq data representing samples from the Cancer Genome Atlas (TCGA) were assessed. 
TCGA
To determine whether MAPT expression is related to low‑grade glioma (LGG) survival rates, RNASeq data representing samples from the Cancer Genome Atlas (TCGA) were assessed. 
Cancer Genome Atlas